Stereotaxis, Inc. Logo

Stereotaxis, Inc.

STXS

(0.5)
Stock Price

2,35 USD

-58.55% ROA

-115.14% ROE

-7.62x PER

Market Cap.

160.846.970,00 USD

31.5% DER

0% Yield

-85.79% NPM

Stereotaxis, Inc. Stock Analysis

Stereotaxis, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Stereotaxis, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (21%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 ROE

The stock's ROE indicates a negative return (-60.9%) on shareholders' equity, suggesting poor financial performance.

3 ROA

The stock's ROA (-38.3%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

4 PBV

The stock's elevated P/BV ratio (4.69x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-4), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Stereotaxis, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Stereotaxis, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Stereotaxis, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Stereotaxis, Inc. Revenue
Year Revenue Growth
2000 0
2001 0 0%
2002 18.900 100%
2003 5.014.877 99.62%
2004 18.816.860 73.35%
2005 15.026.390 -25.23%
2006 27.191.706 44.74%
2007 39.298.809 30.81%
2008 40.365.173 2.64%
2009 51.149.555 21.08%
2010 54.051.237 5.37%
2011 41.987.432 -28.73%
2012 46.562.434 9.83%
2013 38.031.081 -22.43%
2014 35.011.276 -8.63%
2015 37.674.524 7.07%
2016 32.164.116 -17.13%
2017 31.144.100 -3.28%
2018 29.346.617 -6.13%
2019 28.902.550 -1.54%
2020 26.630.035 -8.53%
2021 35.020.862 23.96%
2022 28.147.000 -24.42%
2023 31.196.000 9.77%
2023 26.771.000 -16.53%
2024 18.008.000 -48.66%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Stereotaxis, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2000 8.871.585
2001 13.831.016 35.86%
2002 14.325.389 3.45%
2003 13.541.398 -5.79%
2004 18.437.108 26.55%
2005 17.829.282 -3.41%
2006 21.794.177 18.19%
2007 25.471.809 14.44%
2008 17.422.828 -46.2%
2009 14.260.854 -22.17%
2010 12.244.163 -16.47%
2011 12.886.488 4.98%
2012 8.405.086 -53.32%
2013 5.672.058 -48.18%
2014 5.158.331 -9.96%
2015 6.252.791 17.5%
2016 5.487.609 -13.94%
2017 4.760.806 -15.27%
2018 8.219.387 42.08%
2019 9.021.403 8.89%
2020 8.136.914 -10.87%
2021 10.198.553 20.22%
2022 10.558.000 3.4%
2023 10.672.000 1.07%
2023 10.273.000 -3.88%
2024 9.092.000 -12.99%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Stereotaxis, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 1.625.621
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 18.701.726.000 100%
2008 21.121.164.000 11.46%
2009 15.010.490 -140609.36%
2010 15.022.689 0.08%
2011 16.908.656 11.15%
2012 13.394.556 -26.24%
2013 13.066.103 -2.51%
2014 11.845.289 -10.31%
2015 10.543.741 -12.34%
2016 10.345.338 -1.92%
2017 8.509.153 -21.58%
2018 4.901.170 -73.61%
2019 5.838.158 16.05%
2020 6.364.365 8.27%
2021 13.973.498 54.45%
2022 14.363.000 2.71%
2023 15.732.000 8.7%
2023 14.050.000 -11.97%
2024 15.040.000 6.58%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Stereotaxis, Inc. EBITDA
Year EBITDA Growth
2000 -10.883.435
2001 -13.831.016 21.31%
2002 -21.115.311 34.5%
2003 -23.447.008 9.94%
2004 -26.685.379 12.14%
2005 -39.912.858 33.14%
2006 -45.069.701 11.44%
2007 -47.621.412 5.36%
2008 -36.996.496 -28.72%
2009 -24.749.939 -49.48%
2010 -21.019.466 -17.75%
2011 -35.357.591 40.55%
2012 -10.626.262 -232.74%
2013 -8.840.474 -20.2%
2014 -5.384.664 -64.18%
2015 -5.410.528 0.48%
2016 -11.491.597 52.92%
2017 -5.919.597 -94.13%
2018 -2.457.039 -140.92%
2019 -4.826.859 49.1%
2020 -6.713.815 28.11%
2021 -15.071.334 55.45%
2022 -18.776.000 19.73%
2023 -22.556.000 16.76%
2023 -21.244.000 -6.18%
2024 -23.540.000 9.75%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Stereotaxis, Inc. Gross Profit
Year Gross Profit Growth
2000 0
2001 0 0%
2002 -20.860 100%
2003 963.564 102.16%
2004 8.144.598 88.17%
2005 7.305.684 -11.48%
2006 14.298.957 48.91%
2007 23.952.589 40.3%
2008 26.187.383 8.53%
2009 34.127.922 23.27%
2010 38.486.550 11.33%
2011 29.489.351 -30.51%
2012 31.781.379 7.21%
2013 27.029.780 -17.58%
2014 26.787.896 -0.9%
2015 27.236.366 1.65%
2016 24.634.783 -10.56%
2017 20.389.861 -20.82%
2018 23.629.438 13.71%
2019 22.766.091 -3.79%
2020 18.965.789 -20.04%
2021 23.231.676 18.36%
2022 18.470.000 -25.78%
2023 16.236.000 -13.76%
2023 14.860.000 -9.26%
2024 13.252.000 -12.13%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Stereotaxis, Inc. Net Profit
Year Net Profit Growth
2000 -9.549.116
2001 -17.005.198 43.85%
2002 -21.458.658 20.75%
2003 -24.036.837 10.73%
2004 -27.257.469 11.82%
2005 -43.557.835 37.42%
2006 -45.719.770 4.73%
2007 -48.121.514 4.99%
2008 -43.885.974 -9.65%
2009 -27.494.457 -59.62%
2010 -19.923.487 -38%
2011 -32.031.175 37.8%
2012 -9.238.427 -246.72%
2013 -68.757.589 86.56%
2014 -5.202.441 -1221.64%
2015 -7.352.775 29.25%
2016 -5.286.720 -39.08%
2017 -5.887.410 10.2%
2018 116.756 5142.49%
2019 -4.232.973 102.76%
2020 -6.452.892 34.4%
2021 -8.437.150 23.52%
2022 -19.151.000 55.94%
2023 -22.828.000 16.11%
2023 -20.713.000 -10.21%
2024 -23.332.000 11.22%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Stereotaxis, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 -194
2001 -216 10.23%
2002 -180 -19.44%
2003 -172 -4.65%
2004 -22 -681.82%
2005 -15 -57.14%
2006 -13 -7.69%
2007 -13 -8.33%
2008 -11 -9.09%
2009 -6 -120%
2010 -4 -66.67%
2011 -5 40%
2012 -1 -400%
2013 -6 80%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Stereotaxis, Inc. Free Cashflow
Year Free Cashflow Growth
2002 -22.337.447
2003 -26.527.065 15.79%
2004 -33.349.290 20.46%
2005 -43.325.049 23.03%
2006 -41.288.873 -4.93%
2007 -40.457.870 -2.05%
2008 -30.320.311 -33.43%
2009 -23.792.855 -27.43%
2010 -19.625.515 -21.23%
2011 -32.601.027 39.8%
2012 -12.248.357 -166.17%
2013 -6.331.644 -93.45%
2014 -9.216.055 31.3%
2015 -2.681.652 -243.67%
2016 -6.972.938 61.54%
2017 -4.756.144 -46.61%
2018 -2.812.064 -69.13%
2019 -4.646.166 39.48%
2020 -3.582.668 -29.68%
2021 -4.342.501 17.5%
2022 -10.793.000 59.77%
2023 0 0%
2023 -9.505.000 100%
2024 -3.110.000 -205.63%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Stereotaxis, Inc. Operating Cashflow
Year Operating Cashflow Growth
2002 -22.028.935
2003 -24.469.394 9.97%
2004 -31.813.870 23.09%
2005 -40.986.183 22.38%
2006 -38.982.881 -5.14%
2007 -35.713.494 -9.15%
2008 -28.654.503 -24.63%
2009 -22.308.663 -28.45%
2010 -18.909.745 -17.97%
2011 -31.569.278 40.1%
2012 -12.117.658 -160.52%
2013 -6.331.644 -91.38%
2014 -9.092.143 30.36%
2015 -2.528.501 -259.59%
2016 -6.562.754 61.47%
2017 -4.674.567 -40.39%
2018 -2.546.582 -83.56%
2019 -4.616.680 44.84%
2020 -3.511.772 -31.46%
2021 -2.945.911 -19.21%
2022 -8.415.000 64.99%
2023 0 0%
2023 -9.139.000 100%
2024 -3.088.000 -195.95%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Stereotaxis, Inc. Capital Expenditure
Year Capital Expenditure Growth
2002 308.512
2003 2.057.671 85.01%
2004 1.535.420 -34.01%
2005 2.338.866 34.35%
2006 2.305.992 -1.43%
2007 4.744.376 51.4%
2008 1.665.808 -184.81%
2009 1.484.192 -12.24%
2010 715.770 -107.36%
2011 1.031.749 30.63%
2012 130.699 -689.41%
2013 0 0%
2014 123.912 100%
2015 153.151 19.09%
2016 410.184 62.66%
2017 81.577 -402.82%
2018 265.482 69.27%
2019 29.486 -800.37%
2020 70.896 58.41%
2021 1.396.590 94.92%
2022 2.378.000 41.27%
2023 0 0%
2023 366.000 100%
2024 22.000 -1563.64%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Stereotaxis, Inc. Equity
Year Equity Growth
2000 23.255.756
2002 24.006.646 3.13%
2003 25.266.428 4.99%
2004 58.394.468 56.73%
2005 18.125.842 -222.16%
2006 44.788.992 59.53%
2007 24.194.407 -85.12%
2008 4.770.681 -407.15%
2009 7.641.343 37.57%
2010 10.475.246 27.05%
2011 -18.828.895 155.63%
2012 -18.790.226 -0.21%
2013 -11.701.995 -60.57%
2014 -12.549.718 6.75%
2015 -17.625.654 28.8%
2016 -15.529.452 -13.5%
2017 -20.607.123 24.64%
2018 7.271.618 383.39%
2019 28.524.597 74.51%
2020 40.229.241 29.09%
2021 39.423.936 -2.04%
2022 31.929.000 -23.47%
2023 24.298.000 -31.41%
2023 21.920.000 -10.85%
2024 16.764.000 -30.76%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Stereotaxis, Inc. Assets
Year Assets Growth
2000 25.170.000
2002 32.920.872 23.54%
2003 37.323.419 11.8%
2004 71.187.756 47.57%
2005 36.658.189 -94.19%
2006 69.290.660 47.1%
2007 60.475.794 -14.58%
2008 59.440.365 -1.74%
2009 56.120.516 -5.92%
2010 65.761.792 14.66%
2011 39.931.832 -64.69%
2012 32.165.944 -24.14%
2013 31.076.396 -3.51%
2014 23.880.771 -30.13%
2015 19.226.914 -24.2%
2016 20.965.803 8.29%
2017 10.667.203 -96.54%
2018 18.514.607 42.38%
2019 43.584.754 57.52%
2020 55.455.825 21.41%
2021 60.984.686 9.07%
2022 53.413.000 -14.18%
2023 44.528.000 -19.95%
2023 41.909.000 -6.25%
2024 36.014.000 -16.37%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Stereotaxis, Inc. Liabilities
Year Liabilities Growth
2000 1.914.244
2002 8.914.226 78.53%
2003 12.056.991 26.07%
2004 12.793.288 5.76%
2005 18.532.347 30.97%
2006 24.501.668 24.36%
2007 36.281.387 32.47%
2008 54.669.684 33.64%
2009 48.479.173 -12.77%
2010 55.286.546 12.31%
2011 58.760.727 5.91%
2012 50.956.170 -15.32%
2013 42.778.391 -19.12%
2014 36.430.489 -17.42%
2015 36.852.568 1.15%
2016 36.495.255 -0.98%
2017 31.274.326 -16.69%
2018 11.242.989 -178.17%
2019 15.060.157 25.35%
2020 15.226.584 1.09%
2021 21.560.750 29.38%
2022 21.484.000 -0.36%
2023 20.230.000 -6.2%
2023 19.989.000 -1.21%
2024 19.250.000 -3.84%

Stereotaxis, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.28
Net Income per Share
-0.25
Price to Earning Ratio
-7.62x
Price To Sales Ratio
6.77x
POCF Ratio
-18.18
PFCF Ratio
-18.13
Price to Book Ratio
9.59
EV to Sales
6.36
EV Over EBITDA
-7.09
EV to Operating CashFlow
-17.08
EV to FreeCashFlow
-17.02
Earnings Yield
-0.13
FreeCashFlow Yield
-0.06
Market Cap
0,16 Bil.
Enterprise Value
0,15 Bil.
Graham Number
1.05
Graham NetNet
0.03

Income Statement Metrics

Net Income per Share
-0.25
Income Quality
0.43
ROE
-1.02
Return On Assets
-0.42
Return On Capital Employed
-0.74
Net Income per EBT
1
EBT Per Ebit
0.96
Ebit per Revenue
-0.89
Effective Tax Rate
-0.05

Margins

Sales, General, & Administrative to Revenue
0.6
Research & Developement to Revenue
0.4
Stock Based Compensation to Revenue
0.44
Gross Profit Margin
0.56
Operating Profit Margin
-0.89
Pretax Profit Margin
-0.86
Net Profit Margin
-0.86

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.1
Free CashFlow per Share
-0.1
Capex to Operating CashFlow
-0
Capex to Revenue
0
Capex to Depreciation
0.06
Return on Invested Capital
-1.03
Return on Tangible Assets
-0.59
Days Sales Outstanding
42.76
Days Payables Outstanding
156.49
Days of Inventory on Hand
350.43
Receivables Turnover
8.54
Payables Turnover
2.33
Inventory Turnover
1.04
Capex per Share
0

Balance Sheet

Cash per Share
0,18
Book Value per Share
0,20
Tangible Book Value per Share
0.2
Shareholders Equity per Share
0.2
Interest Debt per Share
0.07
Debt to Equity
0.32
Debt to Assets
0.15
Net Debt to EBITDA
0.46
Current Ratio
2.28
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
23546000
Working Capital
0,02 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
8768000
Debt to Market Cap
0.03

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Stereotaxis, Inc. Dividends
Year Dividends Growth

Stereotaxis, Inc. Profile

About Stereotaxis, Inc.

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri.

CEO
Dr. David Leo Fischel C.A.I.A.
Employee
122
Address
710 North Tucker Boulevard
Saint Louis, 63101

Stereotaxis, Inc. Executives & BODs

Stereotaxis, Inc. Executives & BODs
# Name Age
1 Ms. Kimberly R. Peery CPA
Chief Financial Officer & Secretary
70
2 Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
Chief Executive Officer & Chairman
70
3 Mr. Keith Galloway
Vice President of Operations
70

Stereotaxis, Inc. Competitors

AngioDynamics, Inc. Logo
AngioDynamics, Inc.

ANGO

(1.5)
Cutera, Inc. Logo
Cutera, Inc.

CUTR

(2.0)
AtriCure, Inc. Logo
AtriCure, Inc.

ATRC

(0.5)
EDAP TMS S.A. Logo
EDAP TMS S.A.

EDAP

(0.8)